Literature DB >> 29744350

The gut's feeling on bile acid signaling in NAFLD.

John Y L Chiang1.   

Abstract

Entities:  

Year:  2018        PMID： 29744350      PMCID： PMC5934131          DOI： 10.21037/hbsn.2018.01.02

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  14 in total

1.  Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.

Authors:  Na Jiao; Susan S Baker; Adrian Chapa-Rodriguez; Wensheng Liu; Colleen A Nugent; Maria Tsompana; Lucy Mastrandrea; Michael J Buck; Robert D Baker; Robert J Genco; Ruixin Zhu; Lixin Zhu
Journal:  Gut       Date:  2017-08-03       Impact factor: 23.059

Review 2.  An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.

Authors:  Frank J Gonzalez; Changtao Jiang; Andrew D Patterson
Journal:  Gastroenterology       Date:  2016-09-14       Impact factor: 22.682

3.  Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.

Authors:  Preeti Pathak; Hailiang Liu; Shannon Boehme; Cen Xie; Kristopher W Krausz; Frank Gonzalez; John Y L Chiang
Journal:  J Biol Chem       Date:  2017-05-06       Impact factor: 5.157

4.  Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

Authors:  Changtao Jiang; Cen Xie; Fei Li; Limin Zhang; Robert G Nichols; Kristopher W Krausz; Jingwei Cai; Yunpeng Qi; Zhong-Ze Fang; Shogo Takahashi; Naoki Tanaka; Dhimant Desai; Shantu G Amin; Istvan Albert; Andrew D Patterson; Frank J Gonzalez
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

Review 5.  Bile acids: regulation of synthesis.

Authors:  John Y L Chiang
Journal:  J Lipid Res       Date:  2009-04-03       Impact factor: 5.922

6.  Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.

Authors:  Sama I Sayin; Annika Wahlström; Jenny Felin; Sirkku Jäntti; Hanns-Ulrich Marschall; Krister Bamberg; Bo Angelin; Tuulia Hyötyläinen; Matej Orešič; Fredrik Bäckhed
Journal:  Cell Metab       Date:  2013-02-05       Impact factor: 27.287

7.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

Review 8.  Bile acid signaling in metabolic disease and drug therapy.

Authors:  Tiangang Li; John Y L Chiang
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

9.  Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice.

Authors:  Suzanne Devkota; Yunwei Wang; Mark W Musch; Vanessa Leone; Hannah Fehlner-Peach; Anuradha Nadimpalli; Dionysios A Antonopoulos; Bana Jabri; Eugene B Chang
Journal:  Nature       Date:  2012-07-05       Impact factor: 49.962

Review 10.  Recent advances in understanding bile acid homeostasis.

Authors:  John Yl Chiang
Journal:  F1000Res       Date:  2017-11-20
View more
  3 in total

1.  Circulating bile acid concentrations and non-alcoholic fatty liver disease in Guatemala.

Authors:  Alvaro Rivera-Andrade; Jessica L Petrick; Christian S Alvarez; Barry I Graubard; Andrea A Florio; Maria F Kroker-Lobos; Dominick Parisi; Neal D Freedman; Mariana Lazo; Eliseo Guallar; John D Groopman; Manuel Ramirez-Zea; Katherine A McGlynn
Journal:  Aliment Pharmacol Ther       Date:  2022-04-28       Impact factor: 9.524

Review 2.  Natural Bioactive Compounds as Potential Browning Agents in White Adipose Tissue.

Authors:  Youngshim Choi; Liqing Yu
Journal:  Pharm Res       Date:  2021-03-30       Impact factor: 4.200

3.  Modeling alcohol-associated liver disease in a human Liver-Chip.

Authors:  Janna C Nawroth; Debora B Petropolis; Dimitris V Manatakis; Tengku Ibrahim Maulana; Gabriel Burchett; Katharina Schlünder; Anke Witt; Abhishek Shukla; Konstantia Kodella; Janey Ronxhi; Gauri Kulkarni; Geraldine Hamilton; Ekihiro Seki; Shelly Lu; Katia C Karalis
Journal:  Cell Rep       Date:  2021-07-20       Impact factor: 9.423
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.